Leaders from two New York bioscience and health-care institutions came together at Carnegie Hall to acknowledge the signing of an update to their affiliation agreement initiated in 2015. The Cold Spring Harbor Laboratory (CSHL)-Northwell Health agreement ensures continued collaboration and support for ongoing clinical trials, among other advanced biotechnology initiatives.
Bruce Stillman, PhD
Michael J. Dowling, MSW
“The alliance between [CSHL] and Northwell Health brings transformative bioscience research into the clinic,” said CSHL President and Chief Executive Officer Bruce Stillman, PhD. “As New York’s largest health-care provider, Northwell Health serves a remarkably diverse patient population. This agreement will provide patient communities with greater access to cutting-edge biomedical technology, allowing for more precise diagnoses and treatments and ultimately facilitating new breakthroughs in cancer care.”
“Reaffirming our exclusive strategic affiliation with [CSHL] and Northwell Health marks a pivotal moment in accelerating our efforts to advance cancer research and revolutionize treatment in the fight against cancer,” said Michael J. Dowling, MSW, President and Chief Executive Officer of Northwell Health.
Ongoing Activities
The CSHL–Northwell Health affiliation aims to enhance biology and cancer research at CSHL’s National Cancer Institute–designated Cancer Center and more than 60 research labs, as well as the Feinstein Institutes for Medical Research, the home of research at Northwell Health with 50 research labs and 5,000 researchers and staff systemwide. The affiliation also seeks to translate basic research into clinical applications, provide access to diverse patient populations, and train the next generation of scientist-clinicians. Over the past 10 years, the affiliation has funded 82 research projects.
